Approaches to Hematologic Cancers

Jeffrey Wolf, MD, director of the Myeloma Program at UCSF Health, discusses the traditional approaches to hematologic cancers, including autologous and allogeneic transplant, and how recent advances in immunotherapy -- antibody-drug conjuagtes (ADCs), bi-specific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T cell therapy – are on track to become the standard of care for patients with melanoma.